CRISPR-based identification of N-terminal acetylation in synucleinopathies.

A recent study by Kumar et al. identified several biological pathways that regulate the levels of endogenous alpha-synuclein (α-synuclein). They specifically highlighted the N-terminal acetylation (NTA) pathway as an important factor in maintaining the stability of endogenous α-synuclein, suggesting targeting the NTA pathway as a potential therapeutic approach.
Competing Interests: Declaration of interests S-J.L. is a cofounder and CEO of Neuramedy Co. Ltd. E-J.B. declares no competing interests in relation to this work.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)